JP5814494B2 - Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ感染に対する多糖類ワクチン - Google Patents

Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ感染に対する多糖類ワクチン Download PDF

Info

Publication number
JP5814494B2
JP5814494B2 JP2004552204A JP2004552204A JP5814494B2 JP 5814494 B2 JP5814494 B2 JP 5814494B2 JP 2004552204 A JP2004552204 A JP 2004552204A JP 2004552204 A JP2004552204 A JP 2004552204A JP 5814494 B2 JP5814494 B2 JP 5814494B2
Authority
JP
Japan
Prior art keywords
polysaccharide
pharmaceutical composition
daltons
antibody
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2004552204A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006513166A (ja
JP2006513166A5 (https=
Inventor
ジェラルド ビー． ピアー，
ジェラルド ビー． ピアー，
トマス メイラ−リトラン，
トマス メイラ−リトラン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Brigham and Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc filed Critical Brigham and Womens Hospital Inc
Publication of JP2006513166A publication Critical patent/JP2006513166A/ja
Publication of JP2006513166A5 publication Critical patent/JP2006513166A5/ja
Application granted granted Critical
Publication of JP5814494B2 publication Critical patent/JP5814494B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2004552204A 2002-11-12 2003-11-12 Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ感染に対する多糖類ワクチン Expired - Fee Related JP5814494B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42542502P 2002-11-12 2002-11-12
US60/425,425 2002-11-12
PCT/US2003/036358 WO2004043405A2 (en) 2002-11-12 2003-11-12 Polysaccharide vaccine for staphylococcal infections

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2012222333A Division JP2013010789A (ja) 2002-11-12 2012-10-04 Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ感染に対する多糖類ワクチン
JP2014231224A Division JP6335102B2 (ja) 2002-11-12 2014-11-14 Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ感染に対する多糖類ワクチン

Publications (3)

Publication Number Publication Date
JP2006513166A JP2006513166A (ja) 2006-04-20
JP2006513166A5 JP2006513166A5 (https=) 2006-12-07
JP5814494B2 true JP5814494B2 (ja) 2015-11-17

Family

ID=32312989

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2004552204A Expired - Fee Related JP5814494B2 (ja) 2002-11-12 2003-11-12 Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ感染に対する多糖類ワクチン
JP2012222333A Pending JP2013010789A (ja) 2002-11-12 2012-10-04 Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ感染に対する多糖類ワクチン
JP2014231224A Expired - Fee Related JP6335102B2 (ja) 2002-11-12 2014-11-14 Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ感染に対する多糖類ワクチン
JP2016171443A Pending JP2016204388A (ja) 2002-11-12 2016-09-02 Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ感染に対する多糖類ワクチン
JP2019035315A Pending JP2019089845A (ja) 2002-11-12 2019-02-28 Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ感染に対する多糖類ワクチン

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2012222333A Pending JP2013010789A (ja) 2002-11-12 2012-10-04 Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ感染に対する多糖類ワクチン
JP2014231224A Expired - Fee Related JP6335102B2 (ja) 2002-11-12 2014-11-14 Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ感染に対する多糖類ワクチン
JP2016171443A Pending JP2016204388A (ja) 2002-11-12 2016-09-02 Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ感染に対する多糖類ワクチン
JP2019035315A Pending JP2019089845A (ja) 2002-11-12 2019-02-28 Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ感染に対する多糖類ワクチン

Country Status (18)

Country Link
US (1) US10919956B2 (https=)
EP (1) EP1565478B1 (https=)
JP (5) JP5814494B2 (https=)
KR (1) KR101062525B1 (https=)
CN (1) CN100351260C (https=)
AU (1) AU2003295520B8 (https=)
BR (1) BRPI0316018B8 (https=)
CA (1) CA2501077C (https=)
DK (1) DK1565478T3 (https=)
ES (1) ES2648046T3 (https=)
IL (3) IL167532A (https=)
MX (1) MXPA05005045A (https=)
NO (1) NO341730B1 (https=)
NZ (1) NZ539153A (https=)
PL (1) PL229487B1 (https=)
PT (1) PT1565478T (https=)
WO (1) WO2004043405A2 (https=)
ZA (1) ZA200502607B (https=)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69227127T2 (de) 1992-12-28 1999-04-29 Yoshiki Industrial Co. Ltd., Yonezawa, Yamagata Hebelmechanismus mit festem drehpunkt, drehendem krafteinleitungspunkt und drehendem kraftangriffspunkt und eine einrichtung mit einem derartigen hebel.
US7252828B2 (en) 1998-07-15 2007-08-07 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
WO2004043405A2 (en) 2002-11-12 2004-05-27 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
AU2003290867A1 (en) * 2002-11-12 2004-06-03 The Brigham And Women's Hospital, Inc. Methods and products for treating staphylococcal infections
AU2005236068C1 (en) 2004-04-21 2012-08-30 Beth Israel Deaconess Medical Center, Inc. Poly-N-acetyl glucosamine (PNAG/DPNAG)-binding peptides and methods of use thereof
KR20070058631A (ko) 2004-09-22 2007-06-08 글락소스미스클라인 바이오로지칼즈 에스.에이. 면역원성 조성물
US8445000B2 (en) * 2004-10-21 2013-05-21 Wyeth Llc Immunogenic compositions of Staphylococcus epidermidis polypeptide antigens
AR060187A1 (es) * 2006-03-30 2008-05-28 Glaxosmithkline Biolog Sa Composicion inmunogenica
MY148405A (en) 2006-03-30 2013-04-30 Glaxosmithkline Biolog Sa Immunogenic composition
WO2007141274A2 (en) 2006-06-06 2007-12-13 Crucell Holland B.V. Human binding molecules having killing activity against staphylococci and uses thereof
US7960518B2 (en) 2006-06-06 2011-06-14 Crucell Holland B.V. Human binding molecules having killing activity against enterococci and uses thereof
WO2009114520A2 (en) * 2008-03-10 2009-09-17 Pharmain Corporation Compositions for treatment with metallopeptidases, methods of making and using the same
KR20110031393A (ko) 2008-07-21 2011-03-25 더 브리검 앤드 우먼즈 하스피털, 인크. 합성 베타-1,6 글루코사민 올리고당에 관한 방법 및 조성물
EP2341929B1 (en) 2008-10-06 2017-01-25 University Of Chicago Compositions and methods related to bacterial emp proteins
ES2784957T3 (es) 2009-04-03 2020-10-02 Univ Chicago Composiciones y métodos relacionados con variantes de la proteína A (SPA)
HUE036372T2 (hu) 2009-06-22 2018-07-30 Wyeth Llc Staphylococcus aureus antigének immunogén készítményei
BRPI1011753B8 (pt) 2009-06-22 2021-05-25 Wyeth Llc conjugados imunogênicos de polissacarídeo capsular de staphylococcus aureus de sorotipos 5 e 8, seu uso e composições que os compreendem
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
US8974799B2 (en) 2009-09-30 2015-03-10 Novartis Ag Conjugation of Staphylococcus aureus type 5 and type 8 capsular polysaccharides
BR112012010223A2 (pt) 2009-10-30 2016-12-06 Novartis Ag purificação de staphylococcus aureus tipo 5 e tipo 8 sacarídeos capsulares
SI2547361T1 (sl) 2010-03-17 2021-01-29 SOCPRA - Sceiences et Genie, s.e.c. Bakterijske komponente cepiva iz staphylococcus aureus in njihova uporaba
JP2013523818A (ja) 2010-04-05 2013-06-17 ザ・ユニバーシティー・オブ・シカゴ 免疫反応のエンハンサーとしてのプロテインＡ（ＳｐＡ）抗体に関連する組成物および方法
CA2797052A1 (en) * 2010-04-23 2011-10-27 Ancora Pharmaceuticals Inc. Synthetic oligosaccharides for staphyloccocus vaccine
JP6002128B2 (ja) 2010-07-02 2016-10-05 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ プロテインＡ（ＳｐＡ）変種に関連する組成物および方法
US9095540B2 (en) 2010-09-09 2015-08-04 The University Of Chicago Methods and compositions involving protective staphylococcal antigens
AU2013252883B2 (en) 2012-04-26 2018-05-17 University Of Chicago Staphylococcal coagulase antigens and methods of their use
US20150147328A1 (en) * 2012-05-07 2015-05-28 Mogam Biotechnology Institute Vaccine composition for preventing staphyllococcus aureus infection
EP2854822B1 (en) * 2012-05-30 2020-07-22 The Brigham and Women's Hospital, Inc. Polysaccharide compositions and methods of use
JP2017518373A (ja) * 2014-05-29 2017-07-06 グリーン・クロス・コーポレイションＧｒｅｅｎ Ｃｒｏｓｓ Ｃｏｒｐ． スタフィロコッカス・アウレウス感染疾患の予防または治療用組成物
WO2017010845A1 (ko) * 2015-07-15 2017-01-19 재단법인 목암생명과학연구소 포도상구균 감염 질환의 예방 또는 치료용 조성물
KR101847051B1 (ko) 2016-04-26 2018-04-09 한국외국어대학교 연구산학협력단 병원균에 대한 항생활성을 갖는 펩타이드 및 이를 포함하는 항생 펩타이드 조성물
SG11201901483QA (en) 2016-10-21 2019-03-28 Socpra Sciences Et Genie Sec Vaccine constructs and uses thereof against staphylococcus infections
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
WO2020163512A1 (en) 2019-02-05 2020-08-13 The Brigham And Women's Hospital, Inc. Polysaccharide compositions for use in treating filariasis
EP3736431A1 (en) 2019-05-10 2020-11-11 Mazda Motor Corporation Engine piston and method for manufacturing the same
WO2021041721A1 (en) * 2019-08-27 2021-03-04 OneBioPharma, Inc. Antimicrobial vaccine compositions
US11173199B2 (en) 2019-11-13 2021-11-16 Alopexx Inc. Low contaminant compositions
US10828360B1 (en) 2020-02-04 2020-11-10 OneBioPharma, Inc. Methods for inhibiting biofilm formation

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2842049A (en) * 1954-09-22 1958-07-08 Technicolor Corp Deacetylated chitin mordant
JPS5452794A (en) 1977-09-30 1979-04-25 Kousaku Yoshida Extracting of polysacchride from capusle containing epidermis staphylococus
US4285936A (en) 1979-12-10 1981-08-25 The United States Of America As Represented By The Secretary Of The Army Method for producing a vaccine against bacterial infections caused by pseudomonas aeruginosa
JPS5686121A (en) * 1979-12-14 1981-07-13 Teijin Ltd Antitumor proten complex and its preparation
US4355023A (en) 1980-09-30 1982-10-19 The Massachusetts General Hospital Antibody fragment compositions and process
US4443549A (en) 1981-10-19 1984-04-17 Molecular Genetics, Inc. Production of monoclonal antibodies against bacterial adhesins
US4470925A (en) 1982-05-05 1984-09-11 E. I. Du Pont De Nemours And Company Immunoglobulin half-molecules and process for producing hybrid antibodies
US4462334A (en) 1982-08-19 1984-07-31 Kim Ho K Solar animal structure
US4465776A (en) * 1982-09-27 1984-08-14 Research Corporation Monoclonal antibodies to vitamin B6 and immunoassay method
US4652448A (en) 1982-10-07 1987-03-24 Molecular Genetics, Inc. Use of monoclonal antibodies against bacterial adhesins
US4578458A (en) 1983-03-23 1986-03-25 Brigham And Women's Hospital Mucoid exopolysaccharide vaccine against Pseudomonas aeruginosa
DK219084D0 (da) 1984-05-02 1984-05-02 Frederik Carl Peter Lindberg Antigen
JPS6191131A (ja) 1984-10-09 1986-05-09 Chugai Pharmaceut Co Ltd 医薬品の吸着防止方法および組成物
GB8426463D0 (en) 1984-10-19 1984-11-28 Technology Licence Co Ltd Monoclonal antibodies
NZ214503A (en) 1984-12-20 1990-02-26 Merck & Co Inc Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins, and methods of preparing such polysaccharides and conjugates
FR2581877B1 (fr) 1985-05-14 1987-12-18 Louvain Universite Catholique Conjugue constitue d'une adhesine de paroi de s. mutans, de nature proteique et d'un polysaccharide de s. mutans, sa preparation et son utilisation notamment dans des vaccins anti-caries
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4755381A (en) * 1986-03-27 1988-07-05 Swiss Serum And Vaccine Institute Berne Klebsiella capsular polysaccharide vaccine
US4786592A (en) 1986-06-18 1988-11-22 Scripps Clinic And Research Foundation Neisseria gonorrhoeae lectin useful as a vaccine and diagnostic marker and means for producing this lectin
US5589591A (en) 1986-07-03 1996-12-31 Advanced Magnetics, Inc. Endotoxin-free polysaccharides
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8621910D0 (en) 1986-09-11 1986-10-15 Technology Licence Co Ltd Monoclonal antibodies
FR2619122B1 (fr) 1987-08-03 1990-03-09 Pasteur Institut Procede d'obtention de polyosides capsulaires de staphylocoques, polyosides obtenus, applications de ces polyosides et souches pour la mise en oeuvre du procede
US4859449A (en) 1987-09-14 1989-08-22 Center For Molecular Medicine And Immunology Modified antibodies for enhanced hepatocyte clearance
CA1340506C (en) 1987-11-24 1999-04-20 Nicholas H. Carbonetti Production of gonorrheal pi proteins and vaccines
US5204098A (en) 1988-02-16 1993-04-20 The United States Of America As Represented By The Department Of Health And Human Services Polysaccharide-protein conjugates
US5055455A (en) 1988-09-28 1991-10-08 Brigham And Women's Hospital Capsular polysaccharide adhesin antigen, preparation, purification and use
FR2640628A1 (fr) 1988-12-16 1990-06-22 Commissariat Energie Atomique Oligosaccharides lies (beta)-(1 -> 6) en particulier des 2-acetamido-2-desoxy-glucoses ou - galactoses et leur preparation
JP3436756B2 (ja) 1988-12-19 2003-08-18 アメリカン・サイアナミド・カンパニー 髄膜炎菌のクラスｉの外膜タンパク質のワクチン
CA2039789A1 (en) 1990-04-27 1991-10-28 Samuel J. Danishefsky Calicheamicinone, derivatives and analogs thereof and methods of making the same
US5571511A (en) 1990-10-22 1996-11-05 The U.S. Government Broadly reactive opsonic antibodies that react with common staphylococcal antigens
DE4219159A1 (de) 1992-06-11 1993-12-16 Boehringer Mannheim Gmbh Selbst assemblierende Monoschicht mit kurzkettigen Linkern
US5763191A (en) * 1990-12-12 1998-06-09 Boehringer Mannheim Gmbh Universal binding film
US5352670A (en) 1991-06-10 1994-10-04 Alberta Research Council Methods for the enzymatic synthesis of alpha-sialylated oligosaccharide glycosides
DK0594743T3 (da) 1991-07-12 1999-12-20 Pfizer Kontinuert cellelinje og vaccine mod aviær coccidia
DE69233012T2 (de) 1991-11-22 2003-11-06 Fattom, Ali Ibrahim Mit staphylococcus epidermidis assoziierte oberflächenantigene des typs i
US5872215A (en) * 1991-12-02 1999-02-16 Medical Research Council Specific binding members, materials and methods
ATE156368T1 (de) 1991-12-06 1997-08-15 North Shore Univ Hospital Verfahren zum vermindern von durch medizinische vorrichtungen bedingten infektionen
DK0635132T4 (da) 1992-03-19 2008-08-25 Jackson H M Found Military Med Bredt reaktive opsoniske antistoffer, som reagerer med fælles stafylokok-antigener
US5425946A (en) 1992-08-31 1995-06-20 North American Vaccine, Inc. Vaccines against group C Neisseria meningitidis
US5362754A (en) 1992-11-12 1994-11-08 Univ. Of Tx Md Anderson Cancer Center M-EDTA pharmaceutical preparations and uses thereof
US5688516A (en) 1992-11-12 1997-11-18 Board Of Regents, The University Of Texas System Non-glycopeptide antimicrobial agents in combination with an anticoagulant, an antithrombotic or a chelating agent, and their uses in, for example, the preparation of medical devices
WO1994015640A1 (en) 1993-01-12 1994-07-21 Anthony George Gristina Methods and compositions for the direct concentrated delivery of passive immunity
US5718694A (en) 1993-11-09 1998-02-17 The Board Of Regents Of The University Of Nebraska Inhibition of adherence of microorganisms to biomaterial surfaces by treatment with carbohydrates
US5858350A (en) * 1993-12-01 1999-01-12 Marine Polymer Technologies Methods and compositions for poly-β-1→4-N-acetylglucosamine cell therapy system
CZ292061B6 (cs) 1994-03-17 2003-07-16 Merck Patent Gmbh Jednořetězcové fragmenty protilátek a protilátky proti receptoru epidermálního růstového faktoru, způsob jejich přípravy a farmaceutický prostředek, který je obsahuje
JPH0840932A (ja) 1994-07-29 1996-02-13 Kitasato Inst:The スタフイロコッカス属菌感染症の予防ワクチン及び治療用抗体並びにそれの製造法
AU7339996A (en) 1995-11-06 1997-05-29 Chugai Seiyaku Kabushiki Kaisha Sydnone imine derivatives
US5830539A (en) 1995-11-17 1998-11-03 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon Methods for functionalizing and coating substrates and devices made according to the methods
US6677164B1 (en) 1995-11-21 2004-01-13 Novartis Ag Multivalent polymers, processes for their preparation, and their use for preparing biologically active compounds
US6245735B1 (en) 1996-07-29 2001-06-12 The Brigham And Women's Hospital, Inc. Methods and products for treating pseudomonas infection
US6294177B1 (en) * 1996-09-11 2001-09-25 Nabi Staphylococcus aureus antigen-containing whole cell vaccine
SK40599A3 (en) * 1996-09-26 2000-06-12 Chugai Pharmaceutical Co Ltd Antibody against human parathormone related peptides
CA2284729A1 (en) 1997-04-18 1998-10-29 Novartis Ag Neoglycoproteins
US6235883B1 (en) * 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
TW586934B (en) 1997-05-19 2004-05-11 Sumitomo Pharma Immunopotentiating composition
US5989542A (en) 1997-08-20 1999-11-23 Brigham And Women's Hospital, Inc. Capsular polysaccharides from enterococci
IT1298539B1 (it) 1998-02-03 2000-01-12 Bracco Spa Metodo per la determinazione di infezioni da protesi
US7018637B2 (en) * 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
CA2264970A1 (en) 1998-03-10 1999-09-10 American Cyanamid Company Antigenic conjugates of conserved lipolysaccharides of gram negative bacteria
JP2002511259A (ja) 1998-04-09 2002-04-16 ジェンセット ５’ｅｓｔおよびコードされるヒトタンパク質
US7214487B2 (en) 1998-06-26 2007-05-08 Sunesis Pharmaceuticals, Inc. Methods for identifying compounds that modulate enzymatic activities by employing covalently bonded target-extender complexes with ligand candidates
EP1096952B1 (en) 1998-07-15 2008-05-21 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
US7252828B2 (en) 1998-07-15 2007-08-07 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
EP1117772B1 (en) * 1998-08-31 2012-10-24 The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin Polypeptides and polynucleotides from coagulase-negative staphylococci
CA2356849C (en) 1998-12-16 2008-06-03 Sca Hygiene Products Zeist B.V. Acidic superabsorbent polysaccharides
ES2275499T3 (es) 1999-03-19 2007-06-16 Glaxosmithkline Biologicals S.A. Vacuna contra streptococcus pneumoniae.
WO2002094983A2 (en) 2001-05-16 2002-11-28 The Children's Hospital Of Philadelphia Dna-antibody complexes to enhance gene transfer
US6962813B2 (en) 2001-05-21 2005-11-08 The Brigham And Women's Hospital, Inc. P. aeruginosa mucoid exopolysaccharide specific binding peptides
US7119172B2 (en) 2001-05-21 2006-10-10 The Brigham And Women's Hospital, Inc. P. aeruginosa mucoid exopolysaccharide specific binding peptides
US20030113350A1 (en) 2001-09-19 2003-06-19 Fattom Ali I. Glycoconjugate vaccines for use in immune-compromised populations
CN1344722A (zh) 2001-10-19 2002-04-17 北京盈富安信科技有限公司 1→6连接的氨基葡聚寡糖和糖苷及其合成和应用
AU2002351208A1 (en) 2001-12-03 2003-06-17 Abgenix, Inc. Antibodies against carbonic anhydrase IX (CA IX) tumor antigen
JP2005532415A (ja) * 2001-12-11 2005-10-27 メルク　エンド　カムパニー　インコーポレーテッド スタフィロコッカス・アウレウスエキソポリサッカライド及び方法
CA2471849A1 (en) * 2001-12-28 2003-07-17 Abgenix, Inc. Antibodies against the muc18 antigen
EP1532175B1 (en) 2002-03-22 2012-10-17 Aprogen, Inc. Humanized antibody and process for preparing the same
CA2480052A1 (en) 2002-04-01 2003-10-16 Human Genome Sciences, Inc. Antibodies that specifically bind to gmad
WO2004043405A2 (en) 2002-11-12 2004-05-27 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
AU2003290867A1 (en) 2002-11-12 2004-06-03 The Brigham And Women's Hospital, Inc. Methods and products for treating staphylococcal infections
BRPI0408167B1 (pt) 2003-03-07 2014-10-21 Wyeth Corp Conjugados de polissacarídeo-proteína veículo adesina da superfície estafilocócica para imunização contra infecções nosocomiais
CA2530363C (en) 2003-06-23 2013-05-07 Baxter International Inc. Carrier proteins for vaccines
US9928522B2 (en) 2003-08-01 2018-03-27 Oath (Americas) Inc. Audience matching network with performance factoring and revenue allocation
JP2007501888A (ja) 2003-08-12 2007-02-01 リポクセン テクノロジーズ リミテッド ポリシアル酸誘導体
AU2005236068C1 (en) 2004-04-21 2012-08-30 Beth Israel Deaconess Medical Center, Inc. Poly-N-acetyl glucosamine (PNAG/DPNAG)-binding peptides and methods of use thereof
CA2475736A1 (en) 2004-07-23 2006-01-23 Cyrille Grandjean Vibrio cholerae lps detoxified derivatives and immunogenic compositions containing them
KR20070058631A (ko) 2004-09-22 2007-06-08 글락소스미스클라인 바이오로지칼즈 에스.에이. 면역원성 조성물
GB0426394D0 (en) 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
US20060134141A1 (en) 2004-12-14 2006-06-22 Nabi Biopharmaceuticals Glycoconjugate vaccines containing peptidoglycan
EP1863536A4 (en) 2005-03-14 2011-07-20 Univ Alberta VACCINE BASED ON SYNTHETIC OLIGOSACCHARIDES AGAINST CANDIDA ALBICANS
AR060187A1 (es) 2006-03-30 2008-05-28 Glaxosmithkline Biolog Sa Composicion inmunogenica
MY148405A (en) 2006-03-30 2013-04-30 Glaxosmithkline Biolog Sa Immunogenic composition
KR20110031393A (ko) 2008-07-21 2011-03-25 더 브리검 앤드 우먼즈 하스피털, 인크. 합성 베타-1,6 글루코사민 올리고당에 관한 방법 및 조성물
US8454979B2 (en) * 2009-02-20 2013-06-04 Meisho Co., Ltd. Immunopotentiating composition and process for producing same
WO2012099805A2 (en) 2011-01-19 2012-07-26 Ocean Nanotech, Llc Nanoparticle based immunological stimulation
EP2854822B1 (en) * 2012-05-30 2020-07-22 The Brigham and Women's Hospital, Inc. Polysaccharide compositions and methods of use
US9759721B2 (en) 2013-01-22 2017-09-12 Imicroq, S.L. Rapid method for detection of pathogen

Also Published As

Publication number Publication date
WO2004043405A2 (en) 2004-05-27
JP6335102B2 (ja) 2018-05-30
ES2648046T3 (es) 2017-12-28
IL167532A (en) 2014-12-31
WO2004043405A8 (en) 2004-08-05
US10919956B2 (en) 2021-02-16
IL263585A (en) 2019-01-31
PL377145A1 (pl) 2006-01-23
PT1565478T (pt) 2017-11-14
NO20052828D0 (no) 2005-06-10
AU2003295520A1 (en) 2004-06-03
CA2501077C (en) 2016-06-21
NO20052828L (no) 2005-08-12
MXPA05005045A (es) 2005-07-01
JP2016204388A (ja) 2016-12-08
EP1565478A4 (en) 2007-01-03
JP2013010789A (ja) 2013-01-17
BRPI0316018B1 (pt) 2017-04-04
AU2003295520B2 (en) 2011-04-14
JP2006513166A (ja) 2006-04-20
NO341730B1 (no) 2018-01-15
BR0316018A (pt) 2005-09-20
PL229487B1 (pl) 2018-07-31
IL209149A0 (en) 2011-01-31
WO2004043405A3 (en) 2004-10-21
CN1708506A (zh) 2005-12-14
NZ539153A (en) 2006-11-30
KR20050074582A (ko) 2005-07-18
CN100351260C (zh) 2007-11-28
JP2019089845A (ja) 2019-06-13
KR101062525B1 (ko) 2011-09-06
JP2015042676A (ja) 2015-03-05
AU2003295520B8 (en) 2011-05-19
CA2501077A1 (en) 2004-05-27
EP1565478B1 (en) 2017-08-02
EP1565478A2 (en) 2005-08-24
BRPI0316018B8 (pt) 2021-05-25
DK1565478T3 (da) 2017-11-13
US20050118198A1 (en) 2005-06-02
ZA200502607B (en) 2006-07-26

Similar Documents

Publication Publication Date Title
JP6335102B2 (ja) Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ感染に対する多糖類ワクチン
US7252828B2 (en) Polysaccharide vaccine for staphylococcal infections
KR102282726B1 (ko) 폴리사카라이드 조성물 및 사용 방법
JP5490341B2 (ja) Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ感染のための多糖ワクチン
HK1079214A (en) Polysaccharide vaccine for staphylococcal infections
HK1079214B (en) Polysaccharide vaccine for staphylococcal infections
PL229287B1 (pl) Sposób wytwarzania kształtek rurowych do łączenia odcinków rur z tworzyw sztucznych
HK1121690A (en) Polysaccharide vaccine for staphylococcal infections

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061019

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061019

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091029

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100128

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100430

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100430

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110322

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110616

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110623

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110922

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120604

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121004

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20121019

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140313

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140318

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140415

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140418

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141028

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141031

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141114

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150324

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150415

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150624

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150918

R150 Certificate of patent or registration of utility model

Ref document number: 5814494

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees